Trial reportJournal of translational medicine2007
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Trial report in Journal of translational medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5%
Clinical and Histological Analysis of Photoaging Treatment With Imiquimod Cream 5%
Who cites it
15 citing papers in PubMed, 55 citations in OpenAlex.
- Immunomodulation by imiquimod in patients with high-risk primary melanoma.The Journal of investigative dermatology · 2012Trial
- Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.Genome biology · 2007Trial
- Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.Dermatology (Basel, Switzerland) · 2021Review
- Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.Environmental research · 2020Article
- Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice.PloS one · 2017Article
- Patient satisfaction and reported outcomes on the management of actinic keratosis.Clinical, cosmetic and investigational dermatology · 2017Review
- Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.The Journal of clinical and aesthetic dermatology · 2014Article
- Article
- A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Roles of the immune system in skin cancer.The British journal of dermatology · 2011Review
- TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.Blood · 2011Article
- Current and emerging treatment strategies for the treatment of actinic keratosis.Clinical, cosmetic and investigational dermatology · 2010Article
- The immunologic aspects of poxvirus oncolytic therapy.Cancer immunology, immunotherapy : CII · 2009Review
- Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.The Journal of clinical and aesthetic dermatology · 2009Article
- Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.BMC immunology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to identify the molecular processes responsible for the anti-lesional activity of imiquimod in subjects with actinic keratosis using global gene expression profiling.
methodsA double-blind, placebo-controlled, randomized study was conducted to evaluate gene expression changes in actinic keratosis treated with imiquimod 5% cream. Male subjects (N = 17) with > or = 5 actinic keratosis on the scalp applied placebo cream or imiquimod 3 times a week on nonconsecutive days for 4 weeks. To elucidate the molecular processes involved in actinic keratosis lesion regression by imiquimod, gene expression analysis using oligonucleotide arrays and real time reverse transcriptase polymerase chain reaction were performed on shave biopsies of lesions taken before and after treatment.
resultsImiquimod modulated the expression of a large number of genes important in both the innate and adaptive immune response, including increased expression of interferon-inducible genes with known antiviral, anti-proliferative and immune modulatory activity, as well as various Toll-like receptors. In addition, imiquimod increased the expression of genes associated with activation of macrophages, dendritic cells, cytotoxic T cells, and natural killer cells, as well as activation of apoptotic pathways.
conclusionData suggest that topical application of imiquimod stimulates cells in the skin to secrete cytokines and chemokines that lead to inflammatory cell influx into the lesions and subsequent apoptotic and immune cell-mediated destruction of lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.